Recovery of blood mononuclear cell calceneurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition

Transplantation

Volumn 61, Issue 10, 1996, Pages 1526-1531

  Piccinini, Giampiero ^a   Gaspari, Flavio ^a   Signorini, Orietta ^a   Remuzzi, Giuseppe ^a,b   Perico, Norberto ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

CALCINEURIN; CALMODULIN-BINDING PROTEINS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; PHOSPHOPROTEIN PHOSPHATASE; TIME FACTORS;

EID: 0029954497     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605270-00020     Document Type: Article

References (31)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
2. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1986; 314: 1219.
3. Starzl T, Klintmalm G, Porter K, Iwatsuki S, Schropter G. Liver transplantation with use of cyclosporine A and prednisone. N Engl J Med 1981; 305: 266.
4. Macoviak J, Oyer P, Stinson E, Jamieson S, Baldwin J, Shumway N. Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant Proc 1985; 17 (suppl 2): 97.
5. Traeger J, Dubernard J, Pozza G. Influence of immunosuppressive therapy on the endocrine function of segmental pancreatic allografts. Transplant Proc 1983; 15: 1326.
6. Nussenblatt R, Palestine A, Chan C. Cyclosporine A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophtalmol 1983; 96: 275.
7. Feutren G, Querin S, Chatenoud L, et al. The effects of cyclosporine in twelve patients with severe systemic lupus. In: Schindler R, ed. Cyclosporine in autoimmune diseases. New York: Springer 1985: 366.
8. Forre O, Bjerkhoel F, Salvesen C, et al. An open, controlled, randomized comparison of cyclosporin azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthr Rheum 1987; 30: 88.
9. Tejani A, Gonzales R, Rajpoot D, Sharma R, Pomrantz A. A randomized trial of cyclosporine with low-dose prednisone compared with high-dose prednisone in nephrotic syndrome. Transplant Proc 1988; 20 (suppl 4): 262.
10. Schreiber S. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283.
11. Emmel E, Verweij C, Durand D, Higgins K, Lacy E, Crabtree G. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cells activation. Science 1989; 246: 1617.
12. Fruman D, Burakoff S, Bierer B. Immunophilins in protein folding and immunosuppression. FASEB J 1994; 8: 391.
13. Liu J, Farmer J, Lane W, Friedman J, Weissman I, Schreiber S. Calcineurin is a common target of cyclophilin-cyclosporin A and FK506-FKBP complexes. Cell 1991; 66: 807.
14. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase in T lymphocytes is inhibited by FK506 and cyclosporine A. Proc Natl Acad Sci USA 1992; 89: 3686.
15. Pai S-Y, Fruman DA, Leong T, et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood 1994; 84: 3974.
16. Batiuk TD, Yatscoff RW, Halloran PF. What is the dose-response curve for the effects of cyclosporine on calcineurin and cytokine induction in vivo? Transplant Proc 1994; 26: 2835.
17. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30: 964.
18. Perico N, Remuzzi G. Cyclosporine-induced renal dysfunction in experimental animals and humans. Transplant Rev 1991; 5: 63.
19. Perico N, Ruggenenti P, Gaspari F, et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54: 56.
20. Bertani T, Ferrazzi P, Schieppati A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40: 243.
21. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc Nephrol 1991; 2: S45.
22. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985; 40: 457.
23. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631.
24. Kahan BD, Wideman C, Ried M. The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc 1984; 16: 1195.
25. Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 1989; 58: 453.
26. Read SM, Northcote DH. Minimization of variation in the response to different proteins of the Coomassie Blue G dye binding assay for protein. Anal Biochem 1981; 116: 53.
27. Kahn JC, Shaw LM, Kane MD. Routine monitoring of cyclosporine in whole blood and in kidney tissue using high performance liquid chromatography. J Anal Toxicol 1986; 10: 28.
28. Batiuk TD, Pazderka F, Halloran PF. Cyclosporine-treated renal transplant patients have only partial inhibition of calcineurin phosphatase activity. Transplant Proc 1995; 27: 840.
29. Batiuk TD, Pazderka F, Halloran PF. How do cells recover from inhibition by cyclosporine? Transplant Proc 1994; 26: 2831.
30. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077.
31. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155.